Latiglutenase treatment for celiac disease: symptom and quality of life improvement for seropositive patients on a gluten‐free diet

Summary Background Celiac disease (CD) is a widespread autoimmune disease triggered by dietary gluten that can lead to severe gastrointestinal symptoms. As there is no available treatment other than a lifelong gluten‐free diet, many patients continue to experience chronic symptoms. Aim In this analysis we report on the efficacy of latiglutenase, an orally administered enzyme treatment, for improving multiple gluten‐induced symptoms and consequent quality of life (QOL) due to inadvertent gluten consumption. Methods This analysis is based on data from the CeliAction study of symptomatic patients (ALV003‐1221; NCT01917630). Patients were treated with latiglutenase or placebo for 12 weeks and instructed to respond to a symptom diary daily and to multiple QOL questionnaires at weeks 0, 6 and 12 of the treatment periods as secondary endpoints. The results were stratified by serostatus. Results 398 patients completed the 12‐week CDSD study. In seropositive (but not seronegative) CD patients a statistically significant and dose‐dependent improvement was seen in the severity and frequency of abdominal pain, bloating, tiredness and constipation. In subjects receiving 900 mg latiglutenase, improvements ( P ‐values) in the severity of these symptoms for week 12 were 58% (0.038), 44% (0.023), 21% (0.164) and 104% (0.049) respectively, relative to placebo‐dosed subjects. The reduction in symptoms trended higher for more symptomatic patients. Similar results were observed for the QOL outcome measures. Conclusions Although this study was not powered to definitively establish the benefit of latiglutenase in seropositive CD patients, such patients appear to show symptomatic and QOL benefit from using latiglutenase with meals.